Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulatory effects of valproic acid and UGT polymorphisms on norclozapine plasma levels in clozapine-treated patients with schizophrenia.

Scientific reports - 24 Apr 2026

Sangüesa Estela, Cirujeda Christine, Bernal Ana, Ribate María Pilar, García Cristina Belén

Abstract excerpt

Glucuronidation, catalysed by UGT enzymes, plays a key role in the metabolism of clozapine (CLZ) and its active metabolite, norclozapine (NCLZ). Genetic polymorphisms in UGT1A4 and UGT2B10 can influence NCLZ plasma levels. Co-administration of valproic acid (VPA), commonly used in Treatment Resistant Schizophrenia, has been linked to decreased NCLZ concentrations and increased neutropenia risk. Additionally,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Clozapine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Genotype

Share to Glucuronosyltransferase

Share to Polymorphism, Single Nucleotide

Share to Schizophrenia

Share to Valproic Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 42031976
DOI: 10.1038/s41598-026-50334-3
PMCID: PMC13275896

Genes

CYP1A2
UGT1A4
UGT2B10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulatory effects of valproic acid and UGT polymorphisms on norclozapine plasma levels in clozapine-treated patients with schizophrenia.PMID 42031976Read ↗

Effects of a Novel UGT2B Haplotype and UGT1A4*3 Allele Variants on Glucuronidation of Clozapine In vivo.Semantic proximity Read ↗

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an updateSemantic proximity Read ↗

Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19Semantic proximity Read ↗

Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19Semantic proximity Read ↗

Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.Semantic proximity Read ↗

Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.Semantic proximity Read ↗

Effect of Genetic Variants, Gender, and Co-treatment on Olanzapine Plasma Concentration in Chinese patients with schizophreniaSemantic proximity Read ↗

Pharmacogenetics-Guided Advances in Antipsychotic Treatment.Semantic proximity Read ↗

Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical ImplicationsSemantic proximity Read ↗

Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habitsSemantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.